|
Gene: BAZ1B |
Gene summary for BAZ1B |
Gene summary. |
Gene information | Species | Human | Gene symbol | BAZ1B | Gene ID | 9031 |
Gene name | bromodomain adjacent to zinc finger domain 1B | |
Gene Alias | WBSCR10 | |
Cytomap | 7q11.23 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9UIG0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9031 | BAZ1B | LZE2T | Human | Esophagus | ESCC | 4.47e-05 | 6.80e-01 | 0.082 |
9031 | BAZ1B | LZE4T | Human | Esophagus | ESCC | 3.21e-12 | 3.28e-01 | 0.0811 |
9031 | BAZ1B | LZE7T | Human | Esophagus | ESCC | 1.15e-07 | 6.49e-01 | 0.0667 |
9031 | BAZ1B | LZE8T | Human | Esophagus | ESCC | 6.54e-05 | 1.38e-01 | 0.067 |
9031 | BAZ1B | LZE20T | Human | Esophagus | ESCC | 3.36e-04 | 2.43e-01 | 0.0662 |
9031 | BAZ1B | LZE22T | Human | Esophagus | ESCC | 2.31e-08 | 4.93e-01 | 0.068 |
9031 | BAZ1B | LZE24T | Human | Esophagus | ESCC | 1.73e-25 | 5.76e-01 | 0.0596 |
9031 | BAZ1B | LZE6T | Human | Esophagus | ESCC | 2.59e-03 | 2.03e-01 | 0.0845 |
9031 | BAZ1B | P1T-E | Human | Esophagus | ESCC | 2.74e-16 | 8.74e-01 | 0.0875 |
9031 | BAZ1B | P2T-E | Human | Esophagus | ESCC | 7.37e-49 | 9.54e-01 | 0.1177 |
9031 | BAZ1B | P4T-E | Human | Esophagus | ESCC | 1.43e-35 | 1.04e+00 | 0.1323 |
9031 | BAZ1B | P5T-E | Human | Esophagus | ESCC | 8.17e-28 | 6.70e-01 | 0.1327 |
9031 | BAZ1B | P8T-E | Human | Esophagus | ESCC | 2.58e-32 | 4.83e-01 | 0.0889 |
9031 | BAZ1B | P9T-E | Human | Esophagus | ESCC | 5.94e-23 | 5.46e-01 | 0.1131 |
9031 | BAZ1B | P10T-E | Human | Esophagus | ESCC | 1.17e-51 | 9.34e-01 | 0.116 |
9031 | BAZ1B | P11T-E | Human | Esophagus | ESCC | 2.60e-15 | 7.83e-01 | 0.1426 |
9031 | BAZ1B | P12T-E | Human | Esophagus | ESCC | 3.16e-56 | 1.07e+00 | 0.1122 |
9031 | BAZ1B | P15T-E | Human | Esophagus | ESCC | 9.59e-43 | 9.89e-01 | 0.1149 |
9031 | BAZ1B | P16T-E | Human | Esophagus | ESCC | 6.05e-56 | 1.15e+00 | 0.1153 |
9031 | BAZ1B | P17T-E | Human | Esophagus | ESCC | 1.15e-11 | 6.65e-01 | 0.1278 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
GO:00182124 | Esophagus | ESCC | peptidyl-tyrosine modification | 202/8552 | 378/18723 | 1.34e-03 | 6.39e-03 | 202 |
GO:00181084 | Esophagus | ESCC | peptidyl-tyrosine phosphorylation | 200/8552 | 375/18723 | 1.60e-03 | 7.45e-03 | 200 |
GO:00165721 | Esophagus | ESCC | histone phosphorylation | 27/8552 | 39/18723 | 2.52e-03 | 1.08e-02 | 27 |
GO:001657011 | Liver | Cirrhotic | histone modification | 154/4634 | 463/18723 | 1.92e-05 | 2.57e-04 | 154 |
GO:001657021 | Liver | HCC | histone modification | 283/7958 | 463/18723 | 2.68e-16 | 2.33e-14 | 283 |
GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
GO:00182123 | Oral cavity | OSCC | peptidyl-tyrosine modification | 180/7305 | 378/18723 | 3.63e-04 | 2.22e-03 | 180 |
GO:00181083 | Oral cavity | OSCC | peptidyl-tyrosine phosphorylation | 177/7305 | 375/18723 | 6.86e-04 | 3.83e-03 | 177 |
GO:000632510 | Oral cavity | OSCC | chromatin organization | 190/7305 | 409/18723 | 1.17e-03 | 5.97e-03 | 190 |
GO:0016572 | Oral cavity | OSCC | histone phosphorylation | 24/7305 | 39/18723 | 3.64e-03 | 1.51e-02 | 24 |
GO:001657023 | Oral cavity | EOLP | histone modification | 98/2218 | 463/18723 | 5.58e-09 | 2.96e-07 | 98 |
GO:000632515 | Oral cavity | EOLP | chromatin organization | 84/2218 | 409/18723 | 2.68e-07 | 8.16e-06 | 84 |
GO:00182121 | Oral cavity | EOLP | peptidyl-tyrosine modification | 65/2218 | 378/18723 | 1.25e-03 | 9.02e-03 | 65 |
GO:00181081 | Oral cavity | EOLP | peptidyl-tyrosine phosphorylation | 64/2218 | 375/18723 | 1.65e-03 | 1.09e-02 | 64 |
GO:00063383 | Oral cavity | EOLP | chromatin remodeling | 46/2218 | 255/18723 | 2.34e-03 | 1.44e-02 | 46 |
GO:001657031 | Oral cavity | NEOLP | histone modification | 88/2005 | 463/18723 | 5.59e-08 | 2.23e-06 | 88 |
GO:000632521 | Oral cavity | NEOLP | chromatin organization | 70/2005 | 409/18723 | 4.97e-05 | 6.83e-04 | 70 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BAZ1B | SNV | Missense_Mutation | novel | c.2647G>T | p.Ala883Ser | p.A883S | Q9UIG0 | protein_coding | tolerated(0.18) | benign(0.223) | TCGA-CV-7104-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BAZ1B | SNV | Missense_Mutation | novel | c.502N>G | p.Gln168Glu | p.Q168E | Q9UIG0 | protein_coding | tolerated(0.13) | benign(0.079) | TCGA-F7-8489-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
BAZ1B | SNV | Missense_Mutation | novel | c.3629N>T | p.His1210Leu | p.H1210L | Q9UIG0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-TN-A7HL-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
BAZ1B | insertion | Frame_Shift_Ins | novel | c.2465_2466insTTACATAC | p.Lys822AsnfsTer7 | p.K822Nfs*7 | Q9UIG0 | protein_coding | TCGA-H7-8502-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | SD | ||
BAZ1B | insertion | Frame_Shift_Ins | novel | c.2789_2790insCAATAAAGAAATTCTGCAAATGGAAAACG | p.Asp931AsnfsTer41 | p.D931Nfs*41 | Q9UIG0 | protein_coding | TCGA-HD-8635-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
BAZ1B | SNV | Missense_Mutation | novel | c.2089N>T | p.Arg697Cys | p.R697C | Q9UIG0 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EJ-A6RA-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 8 | Unknown | Unknown | PD |
BAZ1B | SNV | Missense_Mutation | c.1796N>A | p.Pro599His | p.P599H | Q9UIG0 | protein_coding | deleterious(0) | possibly_damaging(0.879) | TCGA-HC-8213-01 | Prostate | prostate adenocarcinoma | Male | <65 | 6 | Unknown | Unknown | SD | |
BAZ1B | SNV | Missense_Mutation | rs782111334 | c.2077C>T | p.Arg693Trp | p.R693W | Q9UIG0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-HC-8266-01 | Prostate | prostate adenocarcinoma | Male | <65 | 8 | Unknown | Unknown | SD |
BAZ1B | SNV | Missense_Mutation | novel | c.2864N>A | p.Arg955His | p.R955H | Q9UIG0 | protein_coding | tolerated(0.12) | possibly_damaging(0.474) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
BAZ1B | SNV | Missense_Mutation | c.773N>A | p.Arg258Gln | p.R258Q | Q9UIG0 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |